Background/Objectives: The resistance mutations EGFR(L858R/T790M/C797S) in epidermal growth factor receptor (EGFR) are key factors in the reduced efficacy of Osimertinib. Predicting the inhibitory effects of Osimertinib derivatives against these mutations is crucial for the development of more effective inhibitors. This study aims to predict the inhibitory effects of Osimertinib derivatives against EGFR(L858R/T790M/C797S) mutations. Methods: Six models were established using heuristic method (HM), random forest (RF), gene expression programming (GEP), gradient boosting decision tree (GBDT), polynomial kernel function support vector machine (SVM), and mixed kernel function SVM (MIX-SVM). The descriptors for these models were selected by the heuristic method or XGBoost. Comprehensive learning particle swarm optimizer was adopted to optimize hyperparameters. Additionally, the internal and external validation were performed by leave-one-out cross-validation (QLOO2), 5-fold cross validation (Q5-fold2) and concordance correlation coefficient (CCC), QF12, and QF22. The properties of novel EGFR inhibitors were explored through molecular docking analysis. Results: The model established by MIX-SVM whose kernel function is a convex combination of three regular kernel functions is best: R2 and RMSE for training set and test set are 0.9445, 0.1659 and 0.9490, 0.1814, respectively; QLOO2, Q5-fold2, CCC, QF12, and QF22 are 0.9107, 0.8621, 0.9835, 0.9689, and 0.9680. Based on these results, the IC(50) values of 162 newly designed compounds were predicted using the HM model, and the top four candidates with the most favorable physicochemical properties were subsequently validated through PEA. Conclusions: The MIX-SVM method will provide useful guidance for the design and screening of novel EGFR(L858R/T790M/C797S) inhibitors.
Predicting EGFR(L858R/T790M/C797S) Inhibitory Effect of Osimertinib Derivatives by Mixed Kernel SVM Enhanced with CLPSO.
阅读:10
作者:Li Shaokang, Dong Wenzhe, Qu Aili
| 期刊: | Pharmaceuticals | 影响因子: | 4.800 |
| 时间: | 2025 | 起止号: | 2025 Jul 23; 18(8):1092 |
| doi: | 10.3390/ph18081092 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
